Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,402 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma.
Haas L, Elewaut A, Gerard CL, Umkehrer C, Leiendecker L, Pedersen M, Krecioch I, Hoffmann D, Novatchkova M, Kuttke M, Neumann T, da Silva IP, Witthock H, Cuendet MA, Carotta S, Harrington KJ, Zuber J, Scolyer RA, Long GV, Wilmott JS, Michielin O, Vanharanta S, Wiesner T, Obenauf AC. Haas L, et al. Among authors: pedersen m. Nat Cancer. 2021 Jul;2(7):693-708. doi: 10.1038/s43018-021-00221-9. Epub 2021 Jul 15. Nat Cancer. 2021. PMID: 35121945 Free PMC article.
BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress.
Roulstone V, Pedersen M, Kyula J, Mansfield D, Khan AA, McEntee G, Wilkinson M, Karapanagiotou E, Coffey M, Marais R, Jebar A, Errington-Mais F, Melcher A, Vile R, Pandha H, McLaughlin M, Harrington KJ. Roulstone V, et al. Among authors: pedersen m. Mol Ther. 2015 May;23(5):931-942. doi: 10.1038/mt.2015.15. Epub 2015 Jan 26. Mol Ther. 2015. PMID: 25619724 Free PMC article.
HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation.
McLaughlin M, Barker HE, Khan AA, Pedersen M, Dillon M, Mansfield DC, Patel R, Kyula JN, Bhide SA, Newbold KL, Nutting CM, Harrington KJ. McLaughlin M, et al. Among authors: pedersen m. BMC Cancer. 2017 Jan 31;17(1):86. doi: 10.1186/s12885-017-3084-0. BMC Cancer. 2017. PMID: 28143445 Free PMC article.
ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment.
Dillon MT, Bergerhoff KF, Pedersen M, Whittock H, Crespo-Rodriguez E, Patin EC, Pearson A, Smith HG, Paget JTE, Patel RR, Foo S, Bozhanova G, Ragulan C, Fontana E, Desai K, Wilkins AC, Sadanandam A, Melcher A, McLaughlin M, Harrington KJ. Dillon MT, et al. Among authors: pedersen m. Clin Cancer Res. 2019 Jun 1;25(11):3392-3403. doi: 10.1158/1078-0432.CCR-18-1821. Epub 2019 Feb 15. Clin Cancer Res. 2019. PMID: 30770349 Free PMC article.
Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer.
Crespo-Rodriguez E, Bergerhoff K, Bozhanova G, Foo S, Patin EC, Whittock H, Buus R, Haider S, Muirhead G, Thway K, Newbold K, Coffin RS, Vile RG, Kim D, McLaughlin M, Melcher AA, Harrington KJ, Pedersen M. Crespo-Rodriguez E, et al. Among authors: pedersen m. J Immunother Cancer. 2020 Aug;8(2):e000698. doi: 10.1136/jitc-2020-000698. J Immunother Cancer. 2020. PMID: 32759235 Free PMC article.
Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade.
Patin EC, Dillon MT, Nenclares P, Grove L, Soliman H, Leslie I, Northcote D, Bozhanova G, Crespo-Rodriguez E, Baldock H, Whittock H, Baker G, Kyula J, Guevara J, Melcher AA, Harper J, Ghadially H, Smith S, Pedersen M, McLaughlin M, Harrington KJ. Patin EC, et al. Among authors: pedersen m. J Immunother Cancer. 2022 Mar;10(3):e004306. doi: 10.1136/jitc-2021-004306. J Immunother Cancer. 2022. PMID: 35314434 Free PMC article.
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma.
Bozhanova G, Hassan J, Appleton L, Jennings V, Foo S, McLaughlin M, Chan Wah Hak CM, Patin EC, Crespo-Rodriguez E, Baker G, Armstrong E, Chiu M, Pandha H, Samson A, Roulstone V, Kyula J, Vile R, Errington-Mais F, Pedersen M, Harrington K, Ono M, Melcher A. Bozhanova G, et al. Among authors: pedersen m. J Immunother Cancer. 2022 Mar;10(3):e004410. doi: 10.1136/jitc-2021-004410. J Immunother Cancer. 2022. PMID: 35338089 Free PMC article.
OX40 and 4-1BB delineate distinct immune profiles in sarcoma.
Melake MJ, Smith HG, Mansfield D, Davies E, Dillon MT, Wilkins AC, Patin EC, Pedersen M, Buus R, Melcher AA, Thway K, Miah AB, Zaidi SH, Hayes AJ, Fenton TR, Harrington KJ, McLaughlin M. Melake MJ, et al. Among authors: pedersen m. Oncoimmunology. 2022 May 9;11(1):2066050. doi: 10.1080/2162402X.2022.2066050. eCollection 2022. Oncoimmunology. 2022. PMID: 35558159 Free PMC article.
2,402 results